Novel approaches and concepts in CV risk screening and ... · Novel approaches and concepts in CV...
Transcript of Novel approaches and concepts in CV risk screening and ... · Novel approaches and concepts in CV...
Novel approaches and concepts in CV risk screening and management
Kausik Ray, MD
Imperial College London
United Kingdom
Professor Kausik Ray
BSc, MBChB. MD, Mphil, FRCP (Lon), FRCP (Ed), FACC, FESC, FAHA
Professor of Public Health
School of Public Health, Imperial College London, UK
Screening for CVD and FH
Disclosures
• Advisory boards PCSK9 – Sanofi/Regeneron, Amgen, Pfizer, Roche, MSD
• NLI/ SC member for Odyssey –(Sanofi/Regeneron), Roche
• Investigator initiated research grant support (Sanofi/Regeneron/Pfizer/Amgen/MSD)
• CME lectures at Symposia (Sanofi/Regeneron, Amgen, Pfizer, AZ, MSD)
Screening- Who is it for?
General Populations
CVD - leading cause of death worldwide
• Current economic burden in the US of $133 million
• Projected costs more than £1 trillion by 2030 according to AHA1
• Most premature CVD deaths (<75 years) are preventable
1Weintraub WS, Daniels SR, Burke LE, et al. Value of Primordial and Primary Prevention for Cardiovascular Disease: A Policy Statement From the American Heart Association. Circulation. 2011 Aug 23. 124(8):967-990.
• Variable death rates for premature CVD from state to state in USA
• If the lowest death rate is observed in all states, 92,000 deaths are preventable 2
2 www.cdc.gov/media/releases/2014/p0501-preventable-deaths.html
CVD deaths are preventable
Use Epidemiological Data to Target those at Risk
Policy Change
• Translate this information into policy change
• Helps raise public awareness
• Provides a systematic approach
The NHS Health Check
The NHS Health Check
Adults aged 40-74 without a pre-existing condition invited for free health screening
Lifestyle questionnaire, BP, Lipid profile, ECG, BMI and Diabetes risk assessment
Follow up results with personalised advice and support
Estimated to prevent 1600 MI/CVAs, 650 premature deaths and >4,000 new diabetes cases/year3
3 www.nhs.uk/Conditions/nhs-health-check/Pages/NHS-Health-Check.aspx
• Assess CVD risk , Screen for DM, CKD
• Early intervention
• Diet, exercise, salt reduction, smoking cessation
• Where needed BP lowering/ Lipid modification
Where do get the biggest pickup
• High Coverage of Health Checks
• Low Socio Economic Groups
• Ethnic Minorities
• Burden of CV risk factors is high
• Ference BA et al. J Am Coll Cardiol 2012;60:2631–2639; Baigent C et al. Lancet 2005;366:1267–1278
Screen early, treat early, think about lifetime risk
rs12916
rs4299376
rs599839
rs11206510
rs2228671rs646776 rs6511720
rs4420638
rs11591147
1.00 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 11.010.0 12.013.014.015.016.017.018.0
10%
20%
30%
Lower LDL-C (mg/dl)
Pro
po
rtio
nal
Ris
k R
edu
ctio
n (S
E)
50%
40%
30%
20%
10%
0%
-10%
0.5 1.0 1.5 2.0
Reduction in LDL cholesterol (mmol/L)
Pro
po
rtio
nal
red
uct
ion
in e
ven
t ra
te (
SE)
Major vascular
events
54.5 % relative risk reductionper 1 mM/L (38.7mg/dl)
LDL-C lowering
22 % relative risk reductionper 1 mM/L (38.7mg/dl)
LDL-C lowering
NICE lipid guidelines: primary prevention
QRISK2 assessment
10-year risk ≥10%
No established CVD
Discuss and support lifestyle changes
Manage other risk factors
Offer atorvastatin20 mg
National Institute for Health and Care Excellence
Lipid modification July 2014 http://www.nice.org.uk/Guidance/CG181
The NHS Health Check
Million Hearts® Project
Million Hearts® Project
Million Hearts® Project
Million Hearts® Project
Launched in 2012 with a goal to prevent 1 million MI/CVA by 2017
Educational campaigns to increase aware of CVD
Standardize and improve delivery of care for hypertension and hypercholesterolemia
Promote smoke-free policies and reduce sodium in food supplies
FH
Familial Hypercholesterolaemia
Estimated millions of individuals worldwide with FH by WHO regions and by income groups
Nordestgaard BG et al. Eur Heart J 2013;34:3478-3490
Estimated % of individuals diagnosedwith FH in different countries/ territories, as a fraction of those theoretically predicted based on a frequency of 1/500 in the general population
Familial Hypercholesterolaemia
Nordestgaard BG et al. Eur Heart J 2013;34:3478-3490
Cumulative LDL-C burden with and without familialhypercholesterolaemia as a function of age of
initiation of statin therapy
CHD, coronary heart disease; CV, cardiovascular; FH, familial hypercholesterolaemia; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
Nordestgaard BG, et al. Eur Heart J 2013;34:3478–90
Despite available treatment approaches, a significant percentage of familial hypercholesterolaemia patients
are not at goal
Cross-sectional study was conducted in outpatient lipid clinics of three academic centres and two regional hospitals. Patient records of known HeFH patients were retrieved and data were reviewed on the use of lipid-lowering medication,
plasma lipids and lipoproteins, safety laboratory results, and reasons for not achieving treatment goals.HeFH, heterozygous familial hypercholesterolaemia; LDL-C, low-density lipoprotein cholesterol.
Pijlman AH, et al. Atherosclerosis 2010;209:189–94.
100
80
40
02
Attainment ofLDL-C
target (%)
LDL-C target (mmol/l)
60
20
0 43 5 6 7 8 9 10
• Only 21% of HeFH patients achieved the LDL-C treatment goal of <2.5 mmol/L
• Of those not at target, 73% did not use maximum statin treatment or combination with ezetimibe
n=1249
Using a modified DLCN criteria
1 in 4 to 1 in 5 infarcts under 50y of age could have FH!
Start Simple
• Early index cases , screen first degree family members
• Apps like FHSCORE based on the Dutch Lipid Network Criteria
• Where you have some evidence of a founder effect, worthwhile to send nurses health care professionals to towns villages where large numbers gather, churches, sporting events, community projects
Treatment
• High intensity statin therapy in adults. Trying to achieve at least a 50% reduction in LDL-C
• BUT
• Think about targets as even a 50% reduction will not normalise risk
• So EAS recommend 2.5mmol/L but for HoFHshould be <1.8mmol/L (Consensus Statement)
• NEED additional LMT- ezetemibe, bile acid absorption inhibitors, PCSK9i
• The burden of FH and its consequences can only be overcome by partnerships between academia, clinicians, patient representatives and policy makers in a coordinated systematic and sustained fashion.
EAS FH Studies Collaboration (FHSC)
Mission:
To empower the medical & global community to seek change in their respective countries ororganizations regarding how FH is detected and managed, with a view to promoting early diagnosis andmore effective treatment of this condition.
Through international collaboration of stakeholders we aim to generate large scale robust data on howFH is detected, managed and the clinical consequences of current practice on outcomes.
To work with all stakeholders including patient’s organizations to ensure that these state-of-the-artinformation are utilized to close gaps in knowledge and/or improve clinical practice for our FH patients.
• International steering committee:
– Prof Kausik K. Ray UK Lead FHSC
– Prof Alberico L. Catapano Italy President EAS
– Dr Handrean Soran UK
– Prof John Kastelein The Netherlands
– Prof G. Kees Hovingh The Netherlands
– Prof Pedro Mata Spain
– Prof Gerald Watts Australia
– Prof Frederick Raal South Africa
– Prof Raul Santos Brazil
Coordinating Centre
EAS FHSC Steering Committee
Coordinating Centre
National Lead investigators
Individual Sites
School of Public Health, ICL
Central point for data collation, cleaning, queries and sharing
Dr. Antonio J. Vallejo-Vaz Lead ScientistDr. Sreenivasa R. Kondapally Seshasai Mrs. Della Cole
• South America an important collaborator
• 4 countries so far
Summary
• Need to think about where the burden of silent disease lies
• Actively go out and look for it’s risk factors in the “latent phase”
• Treat it early and appropriately